Compare · NYXH vs RMD
NYXH vs RMD
Side-by-side comparison of Nyxoah SA (NYXH) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NYXH and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $33.14B, about 409.5x NYXH ($80.9M).
- RMD has been more active in the news (22 items in the past 4 weeks vs 4 for NYXH).
- RMD has more recent analyst coverage (25 ratings vs 9 for NYXH).
- Company
- Nyxoah SA
- ResMed Inc.
- Price
- -
- -
- Market cap
- $80.9M
- $33.14B
- 1M return
- -
- -6.86%
- 1Y return
- -
- -5.86%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 22
- Recent ratings
- 9
- 25
Nyxoah SA
Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest NYXH
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Reports Third Quarter 2026 Financial and Operating Results
- Nyxoah to Release Third Quarter 2026 Financial Results on November 5, 2026
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026
- Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026
- SEC Form 6-K filed by Nyxoah SA
- Nyxoah Appoints Liam Kelly as Chief Executive Officer
Latest RMD
- Chairman and CEO Michael J. Farrell was granted 48,136 units of ResMed Common Stock and covered exercise/tax liability with 28,180 units of ResMed Common Stock, increasing direct ownership by 4% to 491,729 units (SEC Form 4) to satisfy withholding obligation
- Director Christopher Delorefice was granted 554 units of ResMed Common Stock, increasing direct ownership by 23% to 2,977 units (SEC Form 4)
- Global General Counsel Michael J Rider was granted 5,587 units of ResMed Common Stock and covered exercise/tax liability with 3,084 units of ResMed Common Stock, increasing direct ownership by 24% to 12,919 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Ronald R Taylor
- Director Harjit Gill was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 10% to 12,013 units (SEC Form 4)
- Director Desney Tan was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 18% to 7,111 units (SEC Form 4)
- Director John Hernandez was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 22% to 6,227 units (SEC Form 4)
- Director Karen Drexler was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 10% to 11,711 units (SEC Form 4)
- Chief Product Officer Justin Leong was granted 10,314 units of ResMed Common Stock (SEC Form 4)
- Director Carol Burt was granted 1,109 units of ResMed Common Stock, increasing direct ownership by 51% to 3,265 units (SEC Form 4)